Enhertu granted BTD for breast cancer
4 October 2021 07:00 BST Enhertu granted Breakthrough Therapy Designation in US for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens Based on ground-breaking DESTINY-Breast03 results where Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) Enhertu has now been granted four BreakthroughTherapy Designations, including two in breast cancer The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the US for